2.2. Study setting
Kawasaki, pain
GROUP B, KAWASAKI
Study participants include patients with sweating-induced dermal pain who visit Hiroshima University Hospital directly or are referred to Hiroshima University Hospital by collaborating institutions (Kawasaki Medical School Hospital, Kobe University Hospital, and Nagasaki University Hospital) to seek new treatment options. After obtaining consent from study participants at Hiroshima University Hospital, eligibility will be confirmed based on the inclusion and exclusion criteria. Upon enrollment, participants will be assigned to 1 of 2 groups (Icatibant-placebo group [Group A] or Placebo-icatibant group [Group B]). Treatment drugs will be administered in a single-blinded crossover manner, and dermal pain induced by thermal load will be evaluated before and after administration. To explore related mediators, blood and plasma histamine levels and plasma angiotensin-converting enzyme (ACE) levels will also be measured before and after thermal load.